prof. gisbert schneider, phd


Gisbert Schneider has been Full Professor of Computer-Assisted Drug Design at the Institute of Pharmaceutical Sciences in the Department of Chemistry and Applied Biosciences at ETH Zurich since 2010. His research is focussed on the development of methods for virtual screening, molecular de novo design and adaptive autonomous systems in drug research - Gisbert studied biochemistry, medicine and computer science at the Freie Universität Berlin, Germany, where he also earned his doctorate - his postdoc activity included work at the Benjamin Franklin University Clinic in Berlin, MIT, the University of Stockholm, and the Max-Planck-Institute of Biophysics in Frankfurt - Gisbert then spent five years working as a scientific specialist in industrial research at F. Hoffmann-La Roche - in 2000, he received the Venia Legendi for biochemistry and bioinformatics from the University of Freiburg, Germany- from 2002 to 2009, Gisbert worked as a full professor at the Goethe University in Frankfurt, Germany (Beilstein Endowed Chair for Chem- and Bioinformatics).

prof. nissim benvenisty, md phd

science: stem cell biology

Nissim Benvenisty is the Herbert Cohn Chair in Cancer Research, and the director of the Stem Cell Unit at the Hebrew University of Jerusalem - he earned his MD and PhD degrees from the Hebrew University, and conducted postdoctoral studies at Harvard University - his laboratory was the first to demonstrate the differentiation of human ES cells into embryoid bodies, their genetic manipulation and the directed differentiation of the cells – Nissim’s research pioneered in demonstrating the use of human pluripotent stem cells as models for genetic disorders, as well as in studying the immunogenicity of human ES cells, and in suggesting strategies to overcome their tumorigenicity.
he serves on the editorial board of various stem cell-related journals, and is a member of the Board of Directors of the ISSCR - he presented the issue of human ES cells in numerous international conferences, and gave testimonies before the US Senate and the European Union - Nissim was awarded several prizes among them the Foulkes Prize (London), the Hestrin Prize, the Teva Prize, and the Kaye Prize.

gabriela burian, md


Dr. Gabriela Burian is chief medical officer at Iconic Therapeutics, in San Francisco. She has more than 15 years of clinical R&D experience focused on retinal disease, with extensive practice in designing, planning, and executing global clinical programs. Gabriela joined Novartis Pharma in 2005 as a clinical research scientist, where she later held various leadership and management positions including global program medical director and led the global regulatory interactions and approvals process for Lucentis in more than 100 countries. More recently, Gabriela served as the ophthalmology early program leader at
F. Hoffmann-La Roche, where she was responsible for establishing the translational medicine group and leading early clinical development strategy.
Gabriela received her MD from Victor Babes University of Medicine and Pharmacy in Romania, and her Master’s in Public Health in Epidemiology from Rollins School of Public Health at Emory University.

steve arlington, phd


Steve Arlington has long experience in strategy, R&D, regulatory affairs and new product and business development and manufacturing across the pharmaceutical and healthcare sectors - he has over ten years’ experience within the industry in pharmaceutical R&D, both as a project team leader and group research manager - he has also worked in diagnostics and medical devices, and has been involved in the development and launch of world-class drugs and diagnostic tests.
Steve works extensively with company boards and senior management, in the areas of strategy, R&D and regulatory affairs - he has over 20 years of experience in leading complex, multi-national programs.
Steve is a retired partner at PwC, where he led the pharmaceutical team in advisory services - he previously led IBM’s Life Sciences and Pharmaceutical global teams. Steve is the lead author of PwC’s Pharma 2005, Pharma 2010 and Pharma 2020 reports.

dan zabrowski, phd


Dr. Zabrowski worked over 20 years for Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. During his tenure in Business Development and Diagnostics, Dr. Zabrowski and his teams delivered 300+ acquisition and partnership deals. In addition, he was Board member of Chugai Pharmaceuticals.

Prior to joining Roche, Dr. Zabrowski worked at Syntex, Fujisawa (now Astellas) and G.D. Searle in their pharmaceutical R&D organizations and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois — Chicago. Dr. Zabrowski received his PhD in Organic Chemistry from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University.